DEFIANT: Radiofrequency For Chronic Knee Pain Post-Arthroplasty

Sponsor
Randall Brewer, MD, CPI (Other)
Overall Status
Completed
CT.gov ID
NCT02931435
Collaborator
Abbott Medical Devices (Industry), Abbott (Industry)
9
1
2
24
0.4

Study Details

Study Description

Brief Summary

Chronic knee osteoarthritis (OA) is one of the most common diseases with increasing prevalence in advanced age. Knee OA results in movement restriction, sleep disturbance, and disability. Total knee arthroplasty (TKA) is employed often in the symptomatic treatment of knee OA. It has been estimated that 3.4 million TKAs will be performed in the year 2030 in the United States alone. Many studies report rewarding outcomes for patients, but other research shows there are many patients that remain dissatisfied post-arthroplasty.

The purpose of this study is to evaluate whether genicular radiofrequency ablation can relieve chronic post-arthroplasty knee pain.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Nerve Block with Radiofrequency Ablation
  • Procedure: Nerve Block with Sham Radiofrequency Ablation
N/A

Detailed Description

Chronic knee osteoarthritis (OA) is one of the most common diseases with increasing prevalence in advanced age. Knee OA results in movement restriction, sleep disturbance, and disability. Total knee arthroplasty (TKA) is employed often in the symptomatic treatment of knee OA. It has been estimated that 3.4 million TKAs will be performed in the year 2030 in the United States alone. Many studies report rewarding outcomes for patients, but other research shows there are many patients that remain dissatisfied post-arthroplasty.

As the prevalence of knee arthroplasty increases, so does the frequency of revisions. It has been found that 20% of patients reporting painful knee arthroplasties were not able to be diagnosed with a specific cause and were therefore referred to a pain specialist. Pharmacologic therapy and non-surgical interventions are often employed with minimal benefit to the patient's level of disability as indicated by clinical evidence.

Genicular radiofrequency ablation seems to be a safe, effective and minimally invasive therapy for chronic knee OA patients who have had a positive diagnostic block. No study has determined whether genicular radiofrequency ablation can relieve chronic post-arthroplasty knee pain. The investigators propose to examine the effect of genicular radiofrequency ablation in chronic post-arthroplasty knee pain in patients who respond positively to diagnostic nerve blocks.

Study Design

Study Type:
Interventional
Actual Enrollment :
9 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Radiofrequency For The Treatment Of Chronic Knee Pain Following Total Knee Arthroplasty: A Double-Blind Randomized Controlled Pilot Study
Study Start Date :
Dec 1, 2016
Actual Primary Completion Date :
Nov 20, 2018
Actual Study Completion Date :
Nov 30, 2018

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Nerve Block with Radiofrequency Ablation

A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator activation.

Procedure: Nerve Block with Radiofrequency Ablation
Ablation of the genicular nerves of the knee by radiofrequency

Sham Comparator: Nerve Block with Sham Radiofrequency Ablation

A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance.Control patients will undergo the same procedure without RF generator activation. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator sham activation.

Procedure: Nerve Block with Sham Radiofrequency Ablation
Genicular radiofrequency of the knee without neurotomy

Outcome Measures

Primary Outcome Measures

  1. Mean difference in knee pain intensities as indicated on the Visual Analog Scale [Baseline and 6 weeks post-radiofrequency ablation]

Secondary Outcome Measures

  1. Change in Visual Analog Score of average knee pain [Baseline to 1 week, 6 weeks, and 12 weeks]

  2. Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) [Baseline to 1 week, 6 weeks, and 12 weeks]

  3. Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) [Baseline to 1 week, 6 weeks, and 12 weeks]

  4. Change of Patient Global Assessment [Baseline to 1 week, 6 weeks, and 12 weeks]

  5. Satisfaction with Radiofrequency Procedure [Baseline to 1 week, 6 weeks, and 12 weeks]

  6. Rate of procedure-related Adverse Events [From informed consent through study completion, up to 20 weeks]

  7. Rate of Serious Adverse Events [From informed consent through study completion, up to 20 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Study candidate must provide written informed consent.

  • Must be ≥ 50 years of age at the time of consent

  • Chronic knee pain despite total knee arthroplasty at least 6 months prior to consent

  • Orthopedic evaluation indicating no further surgery is warranted

  • Stable pain medication regimen for 30 days prior to baseline visit

  • Knee pain is primary pain complaint

Exclusion Criteria:
  • Acute knee pain

  • Connective tissue disorders affecting the knee

  • Serious neurologic or psychiatric disorders that would affect the outcome of the study as determined by the Principal Investigator

  • Steroid or hyaluronic acid injections into the affected knee in the past 3 months

  • Confounding pain conditions of the index leg that may affect medication requirements or study outcomes

Contacts and Locations

Locations

Site City State Country Postal Code
1 WK River Cities Clinical Research Center Shreveport Louisiana United States 71105

Sponsors and Collaborators

  • Randall Brewer, MD, CPI
  • Abbott Medical Devices
  • Abbott

Investigators

  • Principal Investigator: Randall Brewer, MD, WK River Cities Clinical Research Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Randall Brewer, MD, CPI, Medical Director, Principal Investigator, Willis-Knighton River Cities Clinical Research Center
ClinicalTrials.gov Identifier:
NCT02931435
Other Study ID Numbers:
  • GENRF
First Posted:
Oct 13, 2016
Last Update Posted:
Dec 13, 2018
Last Verified:
Dec 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Keywords provided by Randall Brewer, MD, CPI, Medical Director, Principal Investigator, Willis-Knighton River Cities Clinical Research Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 13, 2018